avium infection by raising glutathione levels, mitigating oxidative stress, and fostering a positive immune response
Subcutaneous Injection Protocol Injectable GHK-Cu typically comes as a lyophilized powder requiring reconstitution with bacteriostatic water
For reconstitution of lyophilised peptide research compounds with Bacteriostatic Water, add the Bacteriostatic Water to the lyophilised powder vial rather than adding powder to water and this ensures complete powder wetting and dissolution without generating undissolved aggregates
The column was then washed with buffer A (300 L, 2,000 g , 2 min), and 10 mM aqueous NH 4 HCO 3 containing 5% CH 3 CN (300 L, 2000 g , 2 min), before peptides were eluted from the column as 15 fractions using 300 L buffer containing an increasing concentration of CH 3 CN in 10 mM NH 4 HCO 3 (%CH 3 CN = 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, 30, 35, 40, 45, 50, 75) (2000 g , 2 min)
Clinical trials are expected to start in the second half of 2023, with topline data due in 2024